DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Belinostat
Belinostat
Vorinostat—An Overview Aditya Kumar Bubna
Peripheral T-Cell Lymphomas
Belinostat (Beleodaq®)
Histone Deacetylase Inhibitors
151109EN ASH Abstract
A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: a Clinical and Translational Study
Medical Drug Benefit Clinical Criteria Updates
Beleodaq® (Belinostat)
Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction
Belinostat and Combo Therapies in T Cell Lymphoma
206256Orig1s000
Histone Deacetylase Inhibitors Dose-Dependently Switch Neutrophil Death from Netosis to Apoptosis
Standard Oncology Criteria C16154-A
Combination Therapy of Bortezomib with Novel Targeted Agents: an Emerging Treatment Strategy
BELEODAQ (Belinostat) for Injection, for Intravenous Administration • Hepatotoxicity: Beleodaq May Cause Hepatic Toxicity and Liver Function Test Initial U.S
Istodax CE Model Poster for AMCP
Spectrum Pharmaceuticals Appoints Steven M. Fruchtman, MD, an Industry Veteran, As Vice President of Clinical Development
Spectrum Pharmaceuticals and Onxeo Announce Complete Response In
Top View
Histone Deacetylase Inhibitors in the Treatment of Multiple Myeloma
Romidepsin and Belinostat Synergize the Antineoplastic Effect of Bortezomib in Mantle Cell Lymphoma
Pharmacogenomic Associations Tables
Spectrum Pharmaceuticals Provides Update on Belinostat Registrational Trial for the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)
Bc Cancer Chemotherapy Preparation and Stability
Profile of Belinostat for the Treatment of Relapsed Or Refractory Peripheral T-Cell Lymphoma
Belinostat: Past and Future
FDA Approval: Belinostat for the Treatment of Patients with Relapsed Or Refractory
Peripheral T-Cell Lymphoma Facts No
BELEODAQ (Belinostat) RATIONALE for INCLUSION in PA PROGRAM
Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma
A Phase I/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas
Clinically Relevant Concentrations of Anticancer Drugs: a Guide for Nonclinical Studies Dane R
Personalized in Vitro and in Vivo Cancer Models to Guide Precision Medicine
Synergistic Antitumor Effects of the Combined Treatment with an HDAC6 Inhibitor and a COX-2 Inhibitor Through Activation of PTEN
Cross Discipline Team Leader Review
Investigator Brochure
HDACI): in Vitro and in Vivo Studies in Thyroid Cancer